Health care stocks saw mixed moves. Deutsche Bank downgraded Novo Nordisk to sell, citing limited growth and patent concerns, with a lower price target. Innovent Biologics received a positive outlook from DBS on potential licensing deals.

Olympus was upgraded by Jefferies on strong margins. Ramsay Health Care impressed with its FY26 results.